Document |
Document Title |
WO/2024/032529A1 |
Provided are a protein degradation agent and a preparation method therefor and a pharmaceutical use thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation method therefor, a ...
|
WO/2024/032409A1 |
The present application relates to the use of a piperazine compound in combination with radiotherapy for the treatment of a tumor.
|
WO/2024/035627A1 |
The present disclosure provides heterocyclic amide and urea compounds and compositions thereof useful for inhibiting JAK2.
|
WO/2024/032689A1 |
The present disclosure relates to a compound of formula (I) or a salt thereof, an enantiomer thereof, a stereoisomer thereof, a solvate thereof, or a polymorph thereof, and use thereof. The present disclosure further relates to a pharmac...
|
WO/2024/033293A1 |
The present invention relates to acylhydrazides obtained in situ by enzymatic hydrolysis of the parent prodrug 2-(difluoromethyl)- or 2-(trifluoromethyl)-1,3,4- oxadiazole, in histone deacetylase 6 (HDAC6).
|
WO/2024/032569A1 |
The present invention provides a prodrug compound, a preparation method therefor and a use thereof. Specifically, the present invention provides a compound represented by formula (I), a preparation method therefor, and a use thereof as a...
|
WO/2024/032561A1 |
Described herein are inhibitors of cyclin-dependent kinase (CDK) 12 and/or CDK13 (and pharmaceutical compositions comprising the inhibitors. The subject compounds and compositions are useful for the treatment of a disease or disorder ass...
|
WO/2024/032776A1 |
Provided are certain BCL-2 inhibitors, pharmaceutical compositions thereof, and methods of use thereof.
|
WO/2024/032782A1 |
Provided is a vaccine adjuvant containing a STING agonist and a use thereof. The vaccine adjuvant containing a STING agonist provided by the present invention can enhance an immune response, and is especially suitable for the prevention ...
|
WO/2024/033667A1 |
The present invention relates to visible light sensitive photoremovable protecting groups and their parent compounds X including a xanthene, xanthenium or related cores, represented by formula (Xa): (Xa) wherein the substituents are as d...
|
WO/2024/029489A1 |
Provided herein are compounds and compositions useful in inhibiting a receptor tyrosine kinase, KIT. The compounds and compositions provided herein are useful for the prevention or treatment of one or more KIT mediated diseases or cond...
|
WO/2024/027762A1 |
Disclosed in the present invention are a fused ring compound, and a preparation method therefor and a use thereof. The present invention provides the fused ring compound represented by formula (I), a stereoisomer thereof, or a pharmaceut...
|
WO/2024/030968A1 |
The present disclosure relates to protein degradation-inducing compounds for protooncogene tyrosine-protein kinase receptor (RET), which may be either wild type RET or a mutant form of RET useful in the treatment of diseases and disorder...
|
WO/2024/031089A1 |
The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
|
WO/2024/027795A1 |
An antibody-drug conjugate containing an Myc protein degradation agent bioactive compound, a preparation method therefor, and use thereof in preventing and/or treating diseases related to abnormal cell activity, including but not limited...
|
WO/2024/027703A1 |
Provided are a PRMT5 inhibitor, and a preparation method therefor and a use thereof. Specifically disclosed are a compound as shown in formula I, a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, and a use thereof in ...
|
WO/2024/027694A1 |
The present invention relates to a protein degradation agent, a preparation method therefor, and a use thereof. The protein degradation agent can degrade various proteins including c-Myc protein, and therefore can be used for prevention ...
|
WO/2024/026536A1 |
The present disclosure relates to a compound of formula (I), or an N-oxide, pharmaceutically acceptable salt, prodrug or stereoisomer thereof. The present disclosure also relates to pharmaceutical compositions comprising the compound. Th...
|
WO/2024/028727A1 |
The present invention discloses a novel type of highly potent ENPP-1 inhibitors for the treatment of various diseases particularly, cancer. These inventive inhibitors are small molecules. One of the novel structural features is incorpora...
|
WO/2024/028795A1 |
The present invention discloses novel compounds as defined by the general formula (I) that are useful for the treatment of diabetes mellitus, obesity, body weight reduction, insulin resistance etc. involving the agonism of the glucagon l...
|
WO/2024/030908A1 |
The present disclosure provides a method of treating an inflammatory disease/disorder, acute myeloid leukemia (AML), or myelodysplastic syndrome (MDS) in a subject comprising administering to the subject a compound that inhibits IRAKI an...
|
WO/2024/028519A1 |
The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, X, Y and A are as defined herein. These compounds are photodynamic agents that generates reactive oxygen species when subjected to UV radiation. The invention also...
|
WO/2024/027565A1 |
The present invention relates to a crystal form of a compound of formula (I), i.e. (2-((5-chloro-2-((2-methoxy-4-(9-methyl-3,9-diaza-spiro[5.5]
undecane-3-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimet
hylphosphine oxide. The present ...
|
WO/2024/028169A1 |
The present invention relates to novel thiophenolic compounds (I) which are useful in the treatment of proliferative and/or hyper-proliferative diseases. Preferably, the compounds of the present invention are endowed with inhibitory acti...
|
WO/2024/028744A1 |
The present invention describes a combination of a suitable prolyl hydroxylase inhibitors with a suitable thrombopoietin (TPO) receptor agonist for the treatment of Aplastic anemia (AA). The invention also describes the preparation of su...
|
WO/2024/027800A1 |
The present invention relates to a new compound as a 5-HT2A receptor inverse agonist, a preparation method therefor and a pharmaceutical composition. The present invention further relates to the use of the compound or the pharmaceutical ...
|
WO/2024/027116A1 |
Provided are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein R1, R2, R3, R4, Q, n, and A are described herein, which are useful as Lp-PLA2 inhibitors, pharmaceutical compositions comprising the ...
|
WO/2024/026688A1 |
The present invention relates to an orange-red thermally activated delayed fluorescent material and a preparation method therefor. The material name is 4,4',4''-(dibenzo[f,h]pyrido[2,3-b]quinoxaline-3,6,11-triyl)
tri(N,N-diphenylaniline)...
|
WO/2024/028316A1 |
The present invention relates to 1H-pyrrolo[3,2-b]pyridine derivatives of formula (I) as irreversible inhibitors of mutant EGFR for the treatment of cancer. An exemplary compound is e.g. N-[2-({4-[3-(4-fluorophenyl)-1H-pyrrolo[3,2-b]pyri...
|
WO/2024/026540A1 |
Disclosed are compounds of Formula I and their use as inhibitors of the viral protease non-structural protein 5 (NSP5). Typically, the NSP5 is derived from a coronavirus, more typically from SARS-CoV-2. More particularly, the invention r...
|
WO/2024/028245A1 |
The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl -peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransfera...
|
WO/2024/026058A1 |
The present invention provides crystalline forms of (6S,7S)-6-fluoro-7-(2-fluoro-5-methylphenyl)-3-(tetrahydro-2
H-pyran-4-yl)-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidine-2,4(
1H,3H)-dione ("Compound I"). Also provided are related pharmace...
|
WO/2024/022434A1 |
The present application relates to a substituted pyridocycloheptane derivative, a preparation method therefor, and use of a pharmaceutical composition comprising the derivative or a deuterated derivative in medicine. In particular, the p...
|
WO/2024/026500A2 |
PDE11A4 inhibitors, and methods of using the same, are provided for treating or preventing diseases or disorder associated with cognitive decline.
|
WO/2024/026290A1 |
The present invention relates to compounds, pharmaceutically acceptable salts of the compounds, and pharmaceutical compositions of the compounds, or salts thereof, that can inhibit secreted phospholipases A2 (sPLA2-X) enzymes, wherein th...
|
WO/2024/026338A1 |
Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.
|
WO/2024/026359A1 |
In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure, in one aspect, relates to compounds that are inhibitors for thioredoxin glutathione reductase (TGR), which is key for ...
|
WO/2024/022266A1 |
The disclosure is related to a series of novel heteroaryl derivatives as USP1 inhibitors useful for the treatment of diseases or conditions, such as cancers, especially cancers with BRCA mutations or HR deficiencies. Specifically, provid...
|
WO/2024/022365A1 |
The present invention relates to a Wnt pathway inhibitor compound represented by formula (I), a pharmaceutical composition comprising the compound, and use of the compound of formula (I) in preventing and/or treating cancers, tumors, inf...
|
WO/2024/022433A1 |
Provided is a class of PRMT5 inhibitors represented by formula (X) or pharmaceutically acceptable salts, isotopic variants, tautomers, stereoisomers, prodrugs, polymorphs, hydrates or solvates thereof. Further provided are a preparation ...
|
WO/2024/025393A1 |
The present invention relates to a novel salt of an imidazo[1,2-a]pyridine compound, a crystalline form thereof, and a preparation method, the novel salt being azetidin-1-yl{8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimid
azo[1,2-a]pyridi...
|
WO/2024/023666A1 |
This application relates to crystalline forms of an inhibitor of AKR1C3 dependent KARS. (Formula I)
|
WO/2024/026081A1 |
The present invention relates to quinazolinones and related compounds which degrade PARP14 and are useful, for example, in the treatment of cancer and inflammatory diseases.
|
WO/2024/023266A1 |
The present invention relates to novel compounds for the treatment, alleviation or prevention of a group of diseases, disorders and abnormalities which are responsive to the modulation or inhibition of the activation of a component of th...
|
WO/2024/021957A1 |
The present invention relates to a PRMT5 inhibitor, a preparation method therefor, and a pharmaceutical use thereof. In particular, the present invention relates to a PRMT5 inhibitor having a compound structure shown in formula (I), a pr...
|
WO/2024/026410A2 |
The present disclosure relates to compounds which inhibit one or more members of the neurotrophic receptor tyrosine kinase (NTRK) family (i.e., NTRK1, NTRK2, and/or NTRK3), and pharmaceutical compositions thereof. In another aspect, the ...
|
WO/2024/017863A1 |
The invention relates to novel compounds having the general formula (I) wherein R4, R5, X1, X2, X3 and Y1 are as described herein, composition including the compounds and methods of using the compounds.
|
WO/2024/017856A1 |
The invention relates to novel compounds having the general formula I wherein R1, R2, X1, X2,X3 and W are as described herein, composition including the compounds and methods of using the compounds.
|
WO/2024/020517A1 |
Provided herein are compounds of formula (II) and formula (I) that are inhibitors of QPCTL and QPCT: (II) & (I) Also provided are pharmaceutical compositions comprising the compounds, as well as the compounds for use in methods for the t...
|
WO/2024/020380A1 |
Substituted quinazoline compounds, conjugates, and pharmaceutical compositions for use in the treatment of cancer are disclosed herein. The disclosed compounds are useful, among other things, in the inhibition of CDK. In certain aspects,...
|